Revolution Medicines, Inc. $RVMD Shares Bought by Ieq Capital LLC

Ieq Capital LLC grew its stake in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 19.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 70,286 shares of the company’s stock after buying an additional 11,452 shares during the quarter. Ieq Capital LLC’s holdings in Revolution Medicines were worth $14,427,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in RVMD. Alphabet Inc. purchased a new stake in shares of Revolution Medicines during the second quarter worth approximately $551,843,000. Assenagon Asset Management S.A. raised its holdings in Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after acquiring an additional 1,980,699 shares in the last quarter. ABS Investment Management LLC purchased a new position in Revolution Medicines in the second quarter worth approximately $337,104,000. Bank of America Corp DE purchased a new position in Revolution Medicines in the second quarter worth approximately $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock worth $170,862,000 after acquiring an additional 411,740 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Stories Impacting Revolution Medicines

Investors following RVMD have been watching these stories:

Analysts Set New Price Targets

RVMD has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their price objective on shares of Revolution Medicines from $260.00 to $321.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Guggenheim raised their price objective on shares of Revolution Medicines from $275.00 to $298.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Oppenheimer lifted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. The Goldman Sachs Group began coverage on shares of Revolution Medicines in a research report on Thursday, September 24th. They set a “buy” rating and a $267.00 price objective for the company. Finally, UBS Group boosted their target price on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $262.75.

View Our Latest Research Report on RVMD

Insider Activity at Revolution Medicines

In related news, insider Stephen Kelsey sold 27,160 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $167.86, for a total value of $4,559,077.60. Following the transaction, the insider directly owned 286,307 shares of the company’s stock, valued at $48,059,493.02. This trade represents a 8.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jack Anders sold 35,750 shares of the stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the completion of the transaction, the chief financial officer directly owned 119,216 shares in the company, valued at $22,424,529.60. This trade represents a 23.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 273,901 shares of company stock valued at $53,970,418 in the last quarter. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $160.63 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34. Revolution Medicines, Inc. has a fifty-two week low of $69.50 and a fifty-two week high of $224.31. The stock’s 50-day simple moving average is $190.01 and its 200-day simple moving average is $161.04.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same period last year, the company earned ($1.61) earnings per share. Equities research analysts forecast that Revolution Medicines, Inc. will post -7.41 EPS for the current year.

About Revolution Medicines

(Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

See Also

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.